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List of Acronyms and abbreviations 
 
TCC- Transitional cell carcinoma 
SCC- Squamous cell carcinoma 
TNM- Tumour, node, metastasis 
TUR- Transurethral resection 
CIS- Carcinoma-in-situ 
BCG- Bacillus Calmette Guerin 







To look at the epidemiology of patients needing this procedure, clinical 
presentation and investigation, pathology, complications related to the 




This is a retrospective review of radical cystectomies done at Groote Schuur 
Hospital from October 1993 to March 2007.  Surgical Research Committee 
and Ethics committee approval was obtained. 105 Patient case notes in folders 
and on microfilms were reviewed. In addition, records kept by the 
stomatherapy and oncology departments were examined. Patients and their 
family were contacted telephonically, in instances where the information in 
the folder was lacking. The vast majority (93/105 or 89%) of patients had 
Transitional cell carcinoma (TCC). 5/105 Patients had Adenocarcinoma (5%) 
and 3/105 patients had Squamous cell carcinoma (3%). For the purposes of 




The mean age of patients undergoing this procedure, was 63 years (Range 45-
78 yrs). The median age was 66 years. The majority of patients were Coloured 
(64/93 or 69%). Very few Black patients underwent this procedure (4/93 or 
4%). The majority of patients were male (77/93 or 83%), smokers (69/93 or 
74%) and presented initially with macroscopic haematuria (77/93 or 83%). 
80/93 (86%) Patients had high grade disease. On pathological staging of these 
tumours (TCC), 45/93 (48%) had extravesical disease (pT3A or greater). It 
must be noted that in 6/93 (6%) patients, no comment is made on the 
pathological stage. 10/93 (11%) Patients had radical cystectomies for 
clinically non-muscle invasive TCC. Of these patients, 5/10 (50%) had 
muscle-invasive TCC on pathological staging, and 4/10 had extravesical 
disease (pT3A or greater). 20/93 (22%) patients with TCC had lymph nodes 
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positive for malignancy. 12/77 (16%) Of men who had radical cystectomies, 
had associated incidental prostate cancer. Intra-operative complications were 
primarily related to massive bleeding (2/93 or 2%), stoma-related difficulties 
(2/93 or 2%) and rectal injury (2/93 or 2%). Early post-operative 
complications were varied, but included wound dehiscence (8/93 or 9%), 
upper GI bleed (3/93 or 3%), DVT (3/93 or 3%), ureteric anastomotic leaks 
(2/93 or 2%) and stoma-related complications (1/93 or 1%). In addition, 2 
rectal injuries manifested as enteric fistula in the first week post-operatively. 
Most late post-operative complications were related to adhesive small bowel 
obstruction (4/93 or 4%) and local recurrence (2/93 had pelvic recurrence, 
2/77 men had urethral recurrence and 1/16 females had a vaginal recurrence). 
One ureteric anastomotic stricture was seen (1/93 or 1%). 
2/93 (2%) of patients received neoadjuvant chemotherapy prior to radical 
cystectomy and 8/93 (9%) patients received adjuvant chemotherapy. 5/93 
(5%) patients received radical radiotherapy as primary treatment, but then 
required salvage cystectomy at a later date. 51/93 (55%) Deaths have been 
documented. 22/93 (24%) Patients are known to still be alive. The following 
statistics apply to the 73/93 patients whose status is definitively known. The 
mean survival is 36 months (3 years). The median survival is 32 months (2.67 
years).   
 
Conclusions 
Patients requiring this procedure are predominantly elderly coloured or white 
males. Very few black patients and a minority of females required radical 
cystectomy. A positive smoking history was a very common association. The 
vast majority of patients present with macroscopic haematuria. Our results 
show, there is a risk of understaging the patient (5/10 or 50% of patients with 
presumed non-muscle invasive disease had muscle invasion on pathological 
staging). Our series of patients with TCC was marked by a high rate of 
extravesical disease (45/93 or 48%), and 20/93 (22%) had positive lymph 
nodes. This is strong evidence that we are not operating on our patients early 
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Radical cystectomy is the standard of care for patients with muscle-invasive 
bladder cancer in the absence of metastatic disease. It includes prostatectomy 
in the male patient, and anterior exenteration in the female, coupled with 
pelvic lymphadenectomy. (1) 
 
 
1. Epidemiology of Bladder cancer 
 
 
63210 new cases of bladder cancer were diagnosed in the United States in 
2005. It is almost three times more common in men than women. In men, it is 
the fourth most common cancer after prostate, lung and colorectal cancers. In 
women, it is the ninth most common cancer. There were approximately 13180 
bladder cancer deaths in 2005 in the United States. They account for 3% of all 
cancer deaths in men and 1.5% in women. (2) 
Bladder cancer can occur at any age. However, it is generally a disease of 
middle-aged and elderly people. The median age at diagnosis is 69 years in 
males, and 71 years in females. (3)  
 
 
2. Aetiology and Risk Factors for Bladder Cancer 
 
 
Factors known to be causally related to the development and progression of 
transitional cell carcinoma include: 
 
1. Cigarette Smoking 
2. Occupational Exposure Risk Factors 
A. Aniline dyes used in Clothing Industry 
B. Acrolein used in Rubber and Textile Industries 
C. Combustion gases and soot from coal 
3. Analgesic abuse 
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4. Pelvic Irradiation 
5. Cyclophosphamide (1) 
 
Squamous cell carcinoma has been related to chronic cystitis and other 
infections, especially Schistosomiasis. (1) 
 
Adenocarcinoma may be related to the urachus, or may be a secondary 
originating from the gastrointestinal tract. (1) 
 
Genes known to be implicated in the development of transitional cell 
carcinoma include: 
 
• P21 RAS oncogene (Chromosome 9p) 
• TP53 (Chromosome 17p) 




Cigarette smokers have up to a four-fold higher incidence of bladder cancer 
than do people who have never smoked. (14, 15) This risk correlates with the 
number of cigarettes smoked, the duration of smoking and the degree of 
inhalation of smoke. (21) Former smokers have a reduced incidence of bladder 
cancer compared with active smokers. (16) However, it takes nearly 20 years 
to reduce this risk down to baseline. (21) Other forms of tobacco use are 
associated with only a slightly higher risk for bladder cancer. (15) The 
evidence regarding increased risk with passive smoking is less clear. It has 
been shown, however, that spouses of long-term cigarette smokers are at 
increased risk. (17) Various compounds have been looked at as potentially 
being responsible for the increased risk of bladder cancer. These include, 
nitrosamines, 2-naphthylamine and 4-aminobiphenyl. In addition, increased 
urinary tryptophan metabolites have been demonstrated in cigarette smokers. 
(40) There is very variable risk of developing bladder cancer in patients with 
seemingly similar exposure. Much attention has been focused on why this may 
be the case. 4-Aminobiphenyl has specifically been looked at. Acetylation of 
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this compound initiates a detoxifying pathway. (21) It has been shown that 
slow acetylators are more susceptible to development of bladder cancer. (41) 
Further study has been directed at the enzymes N-Acetyltransferase 1 and 2. 
Investigators have confirmed that in bladder cancer patients, slow acetylator 
genotypes predominated. (42, 43) The glutathione transferases are another 
enzyme family important in the detoxification of carcinogens. Decreased 
activity of these enzymes is associated with an increased risk of bladder 
cancer. (44) The cytochrome P450 1A2 enzyme demethylates aromatic amines 
resulting in activation of potential carcinogens. Excessive inducibility and 
activity of this enzyme may predispose to greater carcinogen activation and 






Histological subtypes of Urothelial Carcinomas include: 
1. Transitional Cell Carcinoma (TCC) 
• Compromises more than 90% of cases 
2. Squamous Cell Carcinoma (SCC) 
3. Adenocarcinoma 
 
TCC is graded as: 
• Papillary urothelial tumours of low malignant potential 
• Low grade urothelial carcinoma 










Staging is done according to the TNM classification. Muscle-invasive bladder 
cancer is T2 and higher. 
 
 
TABLE 1: 1997 AJCC-UICC TNM Staging 
                                                              
 (5) 
 


















4. Clinical Presentation 
 
 
Painless haematuria is the most common presenting symptom. It occurs in 
about 85% of patients. (6) Some patients may present with frequency, urgency 
and dysuria. With this history, carcinoma-in-situ should be looked for as a 
possible cause. Rarer presentations may include: 
 
• Flank pain from ureteric obstruction 
• Pelvic mass 
• Lower extremity oedema 
• Symptoms of advanced disease e.g. weight loss 






a. Ultrasound of the kidneys, ureter and bladder or an Intravenous 
Pyelogram 
b. Flexible cystoscopy 
c. Urine cytology 
 
 
6. Clinical Staging 
 
 
a. Bimanual examination under anaesthesia 
• If tumour is palpable on bimanual examination before resection, it 
is usually infiltrating into the deep muscle or perivesical tissues 
(21) 
• If a mass is present after trans-urethral resection, the chance of 
extravesical extension is considerable. (21) 
• The teaching at our institution is: 
No mass: T0-T1 
Thickening: T2a 
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Mobile mass: T2b,T3a or b 















The gold standard of treatment for muscle-invasive bladder, in the absence of 
metastases, is radical cystectomy. This includes bilateral pelvic 
lymphadenectomy. (1) Survival after radical cystectomy is related to 

























                   Stage after Radical Cystectomy with and without                                                                                                                                       
 Percentage Disease-Specific Survival by Pathologic                                                                                                                                                                                      
                   Pelvic Lymph Node Metastasis: Selected Series                 
                  (1980-1999) 
 
 
   (1) 
 
 
Patients with organ-confined, muscle-invasive bladder cancer (pT2) had better 
long-term outcomes than patients with disease extending beyond the bladder 
(pT3 and 4a). 
 
 
There are also indications for radical cystectomy in non-muscle invasive 
bladder cancer. The rationale behind this is as follows: 
 
• Despite local therapy, many cases of high-grade non-muscle 
invasive bladder cancer progress to invasion and thus increased 
risk of death (8) 
• In Carcinoma-in-situ (CIS) patients who fail BCG therapy, there is 
a 50% chance of disease progression and potential for disease 
specific mortality (9) 
• Early (<3 months) failure for T1 tumours after BCG therapy is 
associated with an 82% progression rate (10) 
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• Each occurrence of T1 tumour is associated with a 5-10% chance 
of metastasis (11) 
 







The rationale of doing a pelvic lymphadenectomy is that it provides:  
 
• accurate pathological staging 
• prognostic information   
• patients who may benefit from adjuvant chemotherapy 
 
In addition, it doesn’t significantly increase the complication rate of radical 
cystectomy. The risk of developing pelvic lymph node metastases is related to 
the pathological stage of disease. With pT2, the risk is 10-30%, while pT3 
disease is associated with a risk of 30-65%. The obturator and external iliac 
nodes are the groups most commonly involved, with the common iliac and 
presacral nodes less commonly involved. (34) 
 
 
The anatomical limits of the standard pelvic lymph node dissection (PLND) 
are as follows: 
• Lateral limit- Genitofemoral nerve 
• Cephalad limit- External iliac artery and vein dissected up to the                         
                                       bifurcation of the common iliac artery 
• Caudal limit- Endopelvic fascia 





FIGURE 2: Standard Pelvic Lymph Node Dissection 
 
 
GFN- Genitofemoral nerve 
EIA- External iliac artery 
IIA- Internal iliac artery 
U- Ureter 
CIV- Circumflex iliac vein 
EIV- External iliac vein 




Current research suggests that an extended PLND improves survival in both 
lymph node-negative and limited lymph node metastatic disease. (36) An 
extended PLND includes tissue along the common iliacs up to the aortic 















































FIGURE 5: Field of dissection for an extended pelvic lymph 
                     node dissection  






4-right common iliac nodes 
5-left common iliac nodes 
6-right external iliac nodes 
7-left external iliac nodes 
8-presacral nodes 
9-right obturator nodes 
10-left obturator nodes 
11-right internal iliac nodes 
12-left internal iliac nodes 




It has been shown that the lymph node yield can be increased by dissecting 
and submitting separate lymph node packets. (37) This is important as it has 
been shown that the number of lymph nodes removed has prognostic value i.e. 
the more nodes removed, the better the prognosis. (38) 
 
FIGURE 6: Survival related to number of lymph nodes  














The number of positive lymph nodes in the specimen also has prognostic 
value. More than 8 positive nodes was associated with a 10 year recurrence- 
free survival of 10% vs 8 or fewer nodes which was associated with a 40% 
survival. (32) This has led on to the concept of lymph node density, which is 
the total number of positive nodes divided by the total number of extracted 
nodes. As seen in figure 8 below, a lymph node density of 20% or less was 
associated with a 43% 10yr recurrence-free survival whereas a density of 






FIGURE 7: Recurrence-free survival in 244 patients with  
                     lymph node positive disease stratified by lymph  








Neoadjuvant Chemotherapy  
 
This approach involves administration of chemotherapy prior to radical 
cystectomy. Advantages include: 
• Demonstration of chemosensitivity 
• Potential downstaging of the tumour 
• Treatment of micrometastases while patient is not debilitated by 
major surgery. 
There are, however, disadvantages to this approach. These include: 
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• Reliance primarily on clinical as opposed to pathological 
staging, which can result in both under- and over-treatment 
• Delay in undergoing radical cystectomy > 3 months associated 
with worse prognosis (1) 
 
 
TABLE 3: Stratified and unstratified survival analysis of  
                   patients who received neoadjuvant M-VAC + 









           
Current evidence suggests that neoadjuvant chemotherapy + cystectomy 
provides better long term survival than cystectomy alone. This was 
demonstrated in a landmark study by Vogelzang (as shown in Table 3), 







This approach is used in patients with evidence of advanced disease (either 
presence of positive lymph nodes or locally advanced disease) following 
radical cystectomy and pelvic lymphadenectomy. The chemotherapy is given 
so as to reduce the risk of local recurrence or distant metastatic relapse. As 
these patients have been pathologically staged, there is less likelihood of over-
treating them (As compared to patients who have been clinically staged). 
Disadvantages of this approach include: 
 
• Delay in administration of systemic chemotherapy (due to recovery 
time required following cystectomy) 
• Difficulty in assessing tumour response, in the absence of 
radiographically visible disease 
• Patients may not be fit for chemotherapy because of major surgery 
(1). 
 
The evidence suggests that with locoregional disease and pelvic lymph node 




E. Radiation Therapy 
 
 
Preoperative radiotherapy was commonly performed prior to radical 
cystectomy until the 1980’s. The rationale behind this approach was that it 
was thought to treat local micrometastases. Randomized data suggests that in 
patients with T3 disease, local control may be improved by pre-operative 






AIM OF STUDY 
To do a retrospective audit of the radical cystectomies done at Groote Schuur 
Hospital between October 1993 and March 2007, looking specifically at: 
 
1. The spectrum of age, gender and race of patients requiring this 
procedure 
2. Number of smokers vs non-smokers who required this procedure. 
3. Clinical presentation initially 
4. Type of imaging 
• Prescence or absence of Upper tract dilatation 
• Prescence of concurrent Upper tract tumours 
• Diagnosis of bladder lesion 
5. Pathology 
• Clinical vs Pathological staging 
• Ureteric involvement 
• Lymph node involvement 
• Upper tract cancer 
• Incidence of associated Prostate cancer 





7. Patients receiving chemotherapy (Number & Indications) 
• Neoadjuvant 
• Adjuvant 
8. Patients receiving radiotherapy 
• As primary treatment, and then requiring salvage 
cystectomy 
• Post-operatively 




MATERIALS AND METHODS 
 
Surgical and Ethics committee approval was obtained in writing. 105 Patient 
case notes were reviewed. Both patient folders and microfilms were used from 
the Medical Records department at Groote Schuur. Data was obtained 
predominantly from the Urology folder within the patient folder, but the 
patient registration form, anaesthetic notes and pathology result sheet were 
also used. This data was captured in Microsoft Exel. All the relevant data on 
some patients could not be obtained from the folder. The pathology 
department aided us in obtaining some, but not all the data needed. In the 
results section, patient numbers will be indicated in brackets (n). Demographic 
data was recorded as per the Groote Schuur classification noted in the patient 
registration form. Information was supplemented by the Radio-Oncology 
folders and Stomatherapy records. Where necessary, patients and their family 


















For the purposes of this study, I will look specifically at the cohort of patients 
who had radical cystectomy for TCC (93/105 patients or 89%). There were 
5/105 (5%) patients who had Adenocarcinoma, 4/105 (4%) patients had 
Squamous cell carcinoma, and in 2/105 (2%) patients, it was not documented 
what histological type was present. 
RESULTS 
 
1. Socio-economic data 
 
The mean age of patients undergoing this procedure was 63 yrs (Range 45-78 
yrs). The median age was 66 years. 
 
The majority of patients were Coloured (64/93 or 69%). 23/93 (25%) Patients 
were White. Only 4/93 (4%) patients who underwent this procedure were 
Black. In 2/93 (2%) patients, a race classification was not applied. Racial 
classification was according to what was applied by Groote Schuur, and was 
taken directly from the hospital folder 
 























The majority 77/93 (83%) of patients were male. 16/93 (17%) Patients were 
female. 
 

















The majority of patients who underwent radical cystectomy for TCC, were 
smokers 69/93 (74%) . In 5/93 (5%) patients, it was not documented whether 
they were smokers or not. For the purposes of this study, someone who was an 
ex-smoker for greater than 20 years was categorised as a non-smoker. In 
patients who were recorded as ex-smokers, but no time period was specified, 

























3. Initial Presentation 
 
The majority of patients presented initially with macroscopic haematuria 
77/93 (83%). Some patients presented with irritative lower urinary tract 




















FIGURE 12: Initial presentation of patients requiring radical               



















































These imaging modalities told us whether there was hydronephrosis, and gave 
us a clinical suspicion of bladder tumour 
 

































FIGURE 15: Presence/Absence of bladder lesion on imaging  














5. Clinical Staging 
 
 

































49/93 (53%) Patients had a mobile mass on bimanual examination under 
anaesthesia, while 11/93 (12%) patients had a thickening noted on bimanual 
examination under anaesthesia.  
 











The distribution of pre-operative histology is demonstrated in Figure 17. 
The pre-operative histology was used in conjunction with the bimanual 
examination under anaesthesia to clinically stage the patients into non-muscle 


























FIGURE 18: Muscle-invasive vs Non-muscle invasive disease   













































The vast majority (86%) had high grade disease. The grading system has 
changed from when the study period started, hence some G2’s seen. 
 
 
FIGURE 20: Pathological stage of Radical cystectomy  
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On pathological examination of the distal ureters, 1/93 (1%) patients had 
dysplasia in a ureters, 2/93 (2%) patients had Carcinoma-in-situ of the distal 
ureters, and 11/93 (12%) patients had TCC of the distal ureters. 
 










23% of patients had lymph node positive disease. 
 
 
20/93 (22%) Patients had nodes positive for TCC at the time of radical 
cystectomy. If one stratifies these patients for stage, 1/20 (5%) was pT1, 1/20 
(5%) was pT2b, 6/20 (30%) were pT3a, 7/20 (35%) were pT3b, 4/20 (20%) 
were pT4a and 1/20 (5%) was pT4b. Put another way, 18/20 (90%) of patients 
who were node-positive, also had disease which had extended beyond the 
bladder wall. 
 
Of  the 77 men who underwent radical cystectomy for TCC, 2/77 (16%) had 
associated adenocarcinoma of the prostate. They were generally of small 
volume and low Gleason score. In 1/12 (8%) patients, the Gleason score was 













Intra-operative complications were primarily related to massive bleeding 
(>5units packed red blood cells transfused), stoma-related difficulties and 
rectal injury. 
 













For the purposes of this study, early post-operative complications were 
defined as occurring within 2 weeks of radical cystectomy. 8/93 (9%) Patients 
had wound dehiscence. 3/93 (3%) Patients had deep venous thromboses. 3/93 
(3%) Patients had upper gastro-intestinal bleeds. 3/93 (3%) Patients had 
uretero-intestinal anastomotic leaks. 2/93 (2%) Patients developed an enteric 
fistula. 2/93 (2%) Patients had a prolonged ileus requiring total parenteral 
nutrition. 1/93 (1%) Patients had breakdown of their stoma and required their 
ileal conduit to be redone. 
 
For the purposes of this study, late post-operative complications were defined 
as occurring greater than 2 weeks post radical cystectomy. 4/93 (4%) Patients 
developed adhesive small bowel obstruction. In terms of local recurrence, 2/93 









Massive bleeding Rectal injury Stoma-related
 39 
urethral recurrence and 1/16 (6%) female patients developed a vaginal 
recurrence. 1/93 (1%) Patients developed a uretero-intestinal anastomotic 






2/93 (2%) Patients received neoadjuvant chemotherapy prior to radical 
cystectomy. Unfortunately, only 1 of the 2 Oncology folders could be traced. 
This patient had a high grade TCC involving the trigone and bladder neck 
region. There was no muscularis propria in the specimen, and on ultrasound, 
there was left hydronephrosis. He received 3 cycles of Methotrexate, 
Vinblastine and Cisplatin. His radical cystectomy was done approximately 2 
weeks post his 3rd cycle of chemotherapy. His final histology was pT1N0. He 
was contacted telephonically on the 7/02/2010, and is alive and well (Survival 
39 months or 3.25 years).  
 
8/93 (9%) Patients received adjuvant chemotherapy. 1/8 (13%) Patients 
received 4 cycles of Methotrexate, Vinblastine and Cisplatin. 5/8 (63%) 
Patients completed 3 cycles of Methotrexate, Vinblastine and Cisplatin. 1/8 
(13%) Patients developed pyelonephritis after his 1st cycle of Methotrexate, 
Vinblastine and Cisplatin, and was not given the other 2 cycles as the time 
period between 1st and 2nd cycles would have been too great. The oncology 
folder for 1/8 (1%) patients was not traceable. Of the 7/8 patients who have 
records, 5/7 (71%) received adjuvant chemotherapy for positive lymph 
nodes.2/7 (29%) Patients received chemotherapy for non organ-confined 
disease (pT3a and pT3b). 1/8 (13%) Patients had a performance status of 0, 
3/8 (38%) patients had a performance status of 1, 3/8 (38%) patients had a 
performance status of 2, and 1/8 (13%) patients was of unknown performance 
status. Of the 8/93 (9%) patients who underwent adjuvant chemotherapy, there 
have been 3 confirmed deaths. These patients survived for 51 months (4.25 
years), 22 months (1.83 years) and 18 months ((1.5 years) respectively. 2/8 
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(25%) Patients have been confirmed (telephonically) to still be alive. These 
patients have survived for 55 months (4.58 years) and 40 months (3.33 years) 
respectively. The status of the other 3/8 (38%) patients is unknown, despite 
looking at the hospital folder, oncology folder and attempts to contact them or 





5 patients received radical radiotherapy as primary treatment, but then 
required salvage cystectomy at a later date. Records were available for 3/5 
(60%) patients. All received 6 weeks of radiotherapy, 5 fractions per week. 
The time between completion of radiotherapy and radical cystectomy was 5 
months, 5 months and 16 months respectively. 
There was 1 confirmed death. This patient survived 102 months (8.5 years) 
post cystectomy. 1 Patient has been confirmed (telephonically) alive. He has 
survived 135 months (11.25 years) post cystectomy. The status of the other 3 
patients is unknown, despite looking at their hospital records, oncology folder, 






For the purposes of this study, the survival data will be analysed up to and 
including July 2009. It is difficult to definitively comment on survival as some 
patients have been lost to follow up. 51/93 (55%) Deaths have been 
documented. 22/93 (24%) Patients are known to still be alive. These patients 
have either been telephonically contacted, or have been to collect stoma bags. 
The status of the remaining 20/93 (22%) patients is unknown. Efforts to 
ascertain their status included: 
• Reviewing the hospital folders 
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• Reviewing the oncology folders, where available 
• Liasing with stomatherapy and looking at their records, 
including telephoning the day hospitals where the patients 
should have been receiving their stoma bags 
• Telephoning the patients and their families directly 
Of these 24 patients, 13 have had their stomatherapy records archived, which 
means they have not collected stoma bags for at least the past five years. They 
are presumed dead, but this is not known for sure, and if indeed they have 
demised, the dates are unknown. 
 
The following statistics apply to the 73/93 patients whose status is definitively 
known. The mean survival is 36 months (3 years). The median survival is 32 
months (2.67 years). 2/73 (3%) Patients died in the first month after their 
surgery. The longest survivor has survived for 147 months (12.25 years), and 
is still alive.  
 
FIGURE 23: Kaplan Meier graph of survival according to T              





Survival in months according to Tumour stage is represented in the above 
Kaplan Meier graph. From our data it is quite clear that survival is related to 
stage, and with increasing tumour stage, survival decreases. 
 
FIGURE 24: Kaplan Meier graph of survival according to  




Survival in months according to nodal status is represented in the above 
Kaplan Meier graph. From the above data, it is clear that in patients with 
positive lymph nodes, survival is markedly poorer when compared to patients 













Survival according to sex is demonstrated in the above Kaplan Meier graph. In 
our study population, females had a poorer survival than males. This 



















Radical Cystectomy is done predominantly for muscle-invasive bladder 
cancer, and is a major operation associated with both intra- and post-operative 
complications. Patients in our series who required this procedure were 
predominantly elderly coloured or white males. Very few black patients and a 
minority of females required radical cystectomy. We can’t be sure why this is 
the case. Possible theories include: 
 
• Increased exposure to carcinogens eg. Smoking and 
industrial carcinogens, amongst Coloured and White 
males 
• Genetic basis for protective effect amongst the black 
population 
• Black population under-represented at Groote Schuur 
(perhaps related to our drainage area?) 
• Female gender protective? 
 
Further study is needed to prove or disapprove these theories. Hollenbeck et 
al. from the University of Michigan have a published a study on “Racial 
differences in treatment and outcomes among patients with early stage bladder 
cancer.” (49) They used the Surveillance, Epidemiology, and End Results 
(SEER)-Medicare data for the years from 1992 through 2002. In this database, 
there were 14271 white patients, and only 342 black patients. However, they 
note that black patients are at increased risk of death, although the reasons for 
this are unclear. (49) 
 
 
A positive smoking history was a very common association. This association 
is well proven in the literature, with cigarette smokers having up to a fourfold 
higher incidence of bladder cancer than people who have never smoked. (14, 
15) Risk correlates with number of cigarettes smoked and duration of 
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smoking. Ex-smokers have a reduced incidence of bladder cancer compared 
with active smokers. Reduction down to baseline, however, can take up to 20 
years. (16) In our study, it was difficult to assess ex-smokers specifically, as 
the notes were not accurate enough. For the purposes of this study, if it was 
specified that a patient was an ex-smoker for greater than 20 years, they were 
classified as non-smokers. However, in the majority of patients, no time was 
documented as to how long the patient was an ex-smoker, and they were thus 
classified as smokers. In every contact we have with our patients, we would do 
well to warn them of the dangers of smoking and the benefits of stopping. 
These benefits would be not just in terms of reducing the risk of bladder 
cancer, but cardiovascular benefits as well. The evidence regarding increased 
risk in passive smokers is less comprehensive, but an association has been 
demonstrated. (17) 
    
The vast majority (77/93 or 83%) of patients presented with macroscopic 
haematuria. At some stage, they will have had microscopic haematuria. With 
education of healthcare professionals and routine dipstix testing, we could 
potentially identify patients at an earlier stage of disease and thus get better 
results from our surgery. In addition, we may be able to offer patients less 
invasive forms of management. Experience and anecdotal evidence in our 
Haematuria Clinic, however, has shown us that the yield of bladder cancer 
patients from microscopic haematuria, is very low. In our study, only 1/93 
(1%) patients presented with microscopic haematuria. Further study and 
analysis would answer questions of cost-effectiveness. It has been 
demonstrated that a delay in cystectomy of even 12 weeks is associated with 
poorer survival. (23) We don’t have the data in our study to prove patients 
were delayed in receiving definitive surgery from time of presentation and 
therefore had inferior outcomes as a result of this. The reasons for this are 
many: 
• Heterogenous population of patients e.g. some patients were 
sent directly from other hospitals or private, some patients were 
initially managed endoscopically, some patients received 
radical radiotherapy, some  patients received neo-adjuvant 
chemotherapy etc. 
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• Poor record keeping e.g. The duration of macroscopic 
haematuria was not recorded on numerous occasions. 
 
 However, it is logical that we should diagnose and treat these patients as soon 
as possible. We have therefore instituted the Haematuria Clinic at Groote 
Schuur in an effort to make a more rapid diagnosis. Patients may be referred 
directly. They are seen, an ultrasound is done, and they have flexible 
cystoscopy. This is all done on one afternoon by a consultant urologist. A 
patient suspected to have bladder tumour is prioritised to have a transurethral 
resection as soon as possible. The histology from the resection is requested as 
urgent, and once the decision has been made for a radical cystectomy, the 
procedure is usually done within 4 weeks.   
 
 
Ultrasound is the imaging investigation we most commonly employ (46/93 
patients in our series or 49%)). Intravenous pyelography as well as computed 
tomography scanning were also used. Our practice has changed over the 14 




 The reasons for this are: 
 
• It is quick 
• Non-invasive 
• No use of contrast 
• Gives us good information on the state of the upper tracts. 
 
Computed tomography scanning and intravenous pyelograms are rarely done 
in our practice. In the First World, the majority of patients have a computed 
tomography scan of the abdomen and pelvis. Proponents say that this modality 
improves the accuracy of staging by: 
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• Assessing the extent of the primary tumour 
• Presence/Absence of pelvic and para-aortic lymphadenopathy 
• Presence/Absence of visceral metastases (18,19) 
 
Opponents say that all staging studies including computed tomography (with 
the possible exception of transurethral ultrasonography), appear to be 
inaccurate in determining the presence or absence of microscopic muscle 
invasion and minimal extravesical tumour spread. (20) As regards the 
diagnosis of the primary bladder tumour, imaging modalities alone were not 
sensitive enough. A bladder lesion was picked up in 56/93 (60%) of patients 
who had imaging prior to radical cystectomy. Therefore, cystoscopy is still 




Patients with abnormal findings on imaging or cystoscopy, are further 
evaluated with an examination under anaesthesia as well as transurethral 
resection of the tumour. This allows us to make a histological diagnosis as 
well as clinically stage them. However, as our results show, there is a 
significant risk of understaging the patient.  10/93 (11%) Patients had radical 
cystectomies for clinically non-muscle invasive transitional cell carcinoma. Of 
these patients, 5/10 (50%) had muscle-invasive transitional cell carcinoma on 
pathological staging, and 4/10 had extravesical disease (pT3A or greater). 2/10 
(20%) Patients had positive lymph nodes. 
 
This phenomenon is well recognised internationally. Understaging occurs 
most frequently in patients who have high-grade and intermediate-stage 
tumours. Approximately 1/3 of these patients are understaged and 10% are 
overstaged.(22) The greatest danger of clinically understaging a patient, is 
treating them as a non-muscle invasive tumour when they do in fact have 
muscle invasion. It is thus mandatory to repeat the transurethral resection if 
there is no muscle in the initial specimen and the patient has high-grade 
disease. In addition, there is a trend to repeat the cystoscopy and do biopsies at 
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6 weeks in the presence of high-grade disease, even if there is adequate muscle 
in the specimen with no invasion of tumour. Likewise, in patients with high-
grade non-muscle invasive disease (T1G3) and/or Carcinoma-in-situ (CIS) 
who fail Bacillus-Calmette-Guerin (BCG) therapy, there is low threshold for 
doing early Radical Cystectomy. This is because patients with carcinoma-in-
situ who fail BCG therapy, have a 50% chance of disease progression and 
potential for disease-specific mortality. (9, 24) Early (3 months) failure for 
T1G3 tumours after BCG is associated with an 82% progression rate. (10, 25) 
In addition, up to 50% of patients with presumed non-muscle invasive disease, 
who undergo cystectomy will be found actually to have muscle-invasive 
disease (8) and up to 15% will already have micrometastases. (25) There is 
thus a very real chance of missing an opportunity for cure, and operating on 
patients too late. Ongoing efforts at improving the staging of our patients, is 
being made.  Research worldwide into improving imaging techniques and 
modalities is being done. In addition molecular techniques, to detect a variety 
of related gene products is under way.  
 
 
The vast majority of patients (93/105 or 89%) had Transitional cell carcinoma. 
This correlates with international experience. (21) 5/105 (5%) of our patients 
had adenocarcinoma. Generally though, they account for less than 2% of 
primary bladder cancers. (27, 28) 4/105 (4%) had squamous cell carcinoma 
(SCC). The prevalence of SCC is very variable. It accounts for only 1% of 
bladder cancers in England, 3-7% in the US, but as many as 75% in Egypt. 




49/93 (53%) Patients were pathologically staged as having extra-vesical 
disease (pT3a or greater). Our positive lymph node rate was 22% (20/93). 
When one considers that for the duration of the study period, we were only 
doing node sampling for staging purposes, the proportion of patients with node 
positive disease may well have been considerably greater. We are currently 
doing an extended lymph node dissection, and the international literature 
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seems to indicate that this can improve outcome. (31, 32, 33) The above data 
shows that we are operating on patients at an advanced stage. Efforts are being 
made to try and change this pattern and help our patients at an earlier stage. 
These include: 
 
• Education of healthcare professionals with our ongoing 
Undergraduate teaching programme 
• Streamlining the system so that patients have access to 
specialised services faster (Our Urology Outpatient waiting 
period has been drastically reduced to approximately 2 weeks) 
• Creation of the Haematuria clinic 
• Prioritising bladder cancer patients in terms of theatre 
bookings as well requesting histology as urgent. 
 
Associated Carcinoma of the Prostate was found in 12/77 (16%) of the Radical 
Cystectomy specimens in our male patients. The vast majority were of low 
Gleason score and have not proven to be clinically significant. Our rate is a 
little lower than that found in international series, but their experience in the 
clinical insignificance of the lesions has been similar. 
 
 
Intra-operative complications were primarily related to bleeding. Massive 
blood loss (defined as requiring 5 or more units of packed red blood cells) was 
only recorded in 2/93 (2%) patients. Rectal injury was identified in 2 patients 
(2) intra-operatively. 1 patient was primarily repaired and the other underwent 
a colostomy. In addition, 1 missed rectal injury manifested as an entero-
cutaneous fistula in the first post-operative week. This patient underwent a 
colostomy. Extreme difficulty with the stoma was encountered in 2 patients. 1 
patient needed the stoma to be redone 3 times before the surgeons were 
satisfied, and difficulty was encountered in 1 patient in getting the stoma to the 
skin. Contemporary reviews state that catastrophic haemorrhage is rare, but 
can occur during cystectomy. In addition, rectal injury occurs in not more than 
 50 
1 %. Radical cystectomy is associated with a mortality rate of 1-2%. (1) In this 
series, there has not been any intra-operative mortality. 
 
 
Post-operative complications are divided into early (<2 weeks post surgery) 
and late (>2 weeks). Early complications that were seen include: 
 
• Wound dehiscence 8/93 (9%) 
• Upper GI bleed 3/93 (3%) 
• Prolonged urine leak 3/93 (3%) 
• Deep vein thrombosis 3/93 (3%). 
• Stoma complications 1/93 (1%) 
o 1 patient needed the conduit to be redone because of 
breakdown 
• 2/93 (2%) Patients had a prolonged ileus requiring total 
parenteral nutrition. Although often not documented, post-
operative ileus is a very common problem following Radical 
Cystectomy 
 
With the above knowledge in my mind, Groote Schuur Urology have 
implemented uniform protocols in an effort to prevent these complications. 
• A review of wound closure techniques was presented at an academic 
meeting. Very close attention is now paid to the technical aspects of 
the abdominal closure. 
•  All patients receive sucralfate while in ICU, and cimetidine in the 
ward, post-operatively until they are tolerating a full ward diet. There 
is some evidence to suggest the use of Cimetidine to prevent post-
surgical stress ulceration. (50, 51) However, this is for intravenous and 
not oral use. In addition, antacids have been shown to be more 
effective, cheaper and safer than cimetidine. (52) 
• All patients are placed on Heparin 5000u subcutaneously 8-hourly 
from day 1 post-operatively. Leg stockings are applied and patients are 
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encouraged to mobilise early. Contemporary series show that post-
operative pulmonary embolism is rare (2%). (1)  
• In addition, we give all patients a positive end expiratory pressure 
bottle to blow on in order to prevent post-operative atelectasis.  
 
Late post-operative complications seen were: 
 
• Pelvic recurrence 2/93 (2%) 
• Urethral recurrence in males 2/77 (3%) 
• Vaginal recurrence 1/16 (6%) 
• Adhesive small bowel obstruction 4/93 (4%) 
• Uretero-ileal anastomotic stricture 1/93 (1%) 
 
Contemporary series record an anastomotic stricture rate of 3%. (1) In this 
study, the patient with uretero-ileal obstruction was due to recurrent disease. 
He was treated with an indwelling nephrostomy tube. Special mention should 
be made of the pelvic recurrence rate of 2/93 (2%) which is vey low, 
especially considering that many of these patients were operated on at an 
advanced stage of disease. Urethrectomy is not routinely done at our 
institution. However, there is a risk of recurrence, urethral washings are done 
on follow up, and any patient with urethral bleeding is urgently evaluated. 
 
Neo-adjuvant chemotherapy was given to 2/93 (2%) patients and adjuvant 
chemotherapy was given to 8/93 (9%) patients. These 2 approaches have been 
discussed at length in the preceding literature review. At Groote Schuur, 3 
cycles of adjuvant Cisplatin, Methotrexate and Vinblastine (CMV) 
chemotherapy is favoured for extravesical as well as nodal disease. Although 
not regarded as the standard of care, the above regimen is considerably less 
toxic than one with Adriamycin added. In addition, due to cost constraints, 





Median survival was 36 months (3 years). Median survival was 32 months   
(2.67 years). Survival was related to stage. With increasing pathological stage, 
survival decreased. This is well recognised in international series. (1, Table 2) 
Extravesical disease is associated with a poor outcome when compared to 
organ-confined disease. Lymph node positive disease has a very poor 
prognosis. Although mean survival for lymph node positive disease was 15 
months, the median survival was only 6 months. In our study population, 
females did significantly worse than males in terms of survival. 9/11 (82%) 
Females had extravesical disease and 3/11 (27%) had positive lymph nodes. 
























• Radical cystectomy at our institution is needed predominantly for 
white and coloured patients 
• The vast majority of patients are male 
• Most patients were smokers 
• Ultrasound is used for evaluating the upper tracts, and while it may 
diagnose a bladder lesion, it has a very poor sensitivity for this purpose 
• Cystoscopy is thus mandatory in a patient with suspected bladder 
cancer 
• There is a significant risk of clinically understaging the patient 
• Wound dehiscence, upper gastrointestinal haemorrhage and deep vein 
thrombosis were some of the commonest complications seen, and steps 
have been taken to address these. 
• The risk of local recurrence after Radical Cystectomy is low 
• Survival is related to the stage of disease and the status of the lymph 
nodes: 
o Extravesical disease has a poor prognosis 
o Lymph node disease has an extremely poor prognosis 
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